CompletedPhase NA

The Role of Endogenous GLP-1 (Glycolipoprotein) in Regulating Glucose Stimulated Brain Activity

The Role of Endogenous GLP-1 in Regulating Glucose Stimulated Brain Activity

Lead sponsor

University Hospital, Basel, Switzerland

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

•Male•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01918566

Org study IDEKBB 298/12

Timeline

Milestones

Study first posted2013-08-07estimated

Last update posted2013-08-07estimated

Study start2012-03 (month precision)

Primary completion2013-03actual (month precision)

Study completion2013-03actual (month precision)

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age18 Years

Maximum age35 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•right-handed healthy males, no drugs, non-smoking

Exclusion criteria

•drug abuse, smoker, left-handed, claustrophobia

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.